生脉注射液对慢阻肺急性发作期临床症状及炎症指标的影响

Effects of the Shengmai injection on clinical symptoms and inflammatory markers of chronic obstructive pulmonary disease during the acute attack stage

目的:观察生脉注射液对慢阻肺急性发作期临床症状及炎症指标的影响。方法:将62例慢阻肺急性发作期患者随机分为治疗组和对照组,对照组给予常规抗炎、平喘等治疗,治疗组在对照组的基础上加用生脉注射液静滴,疗程均为2周。观察治疗后患者临床症状改善情况及外周血超敏C反应蛋白下降情况。结果:两组治疗后临床症状显著改善,治疗组有效率高于对照组,差别均有统计学意义(P<0.05)。两组外周血C反应蛋白均较治疗前下降,治疗组优于对照组,差别具有统计学意义(P<0.05)。结论:生脉注射液能显著提高慢性阻塞性肺病急性发作期的临床治疗效果,并能抑制外周血炎症介质。

Objective： To observe effects of Shengmai injection on clinical symptoms and inflammatory markers of COPD during acute exacerbation. Methods： 62 cases with COPD were divided into the treatment group and the control group, the control group was treated by the conventional anti-inflammatory and relieving asthma, The treatment group was treated by Shengmai injection more, With two weeks. Observed after treatment the clinical symptoms and peripheral C reactive protein degradation. Results： Clinical symptoms after treatment significantly were improved by the two groups; The effective rate of the treatment group was better than the control group; The difference was statistically significant （P〈0.05）. Serum C reactive protein in two group were lower than before; the treatment groups than the control group; The difference was statistically significant （P〈0.05）. Conclusion： The Shengmai injection can significantly improve clinical curative effects on the acute exacerbation of COPD, and can inhibit the inflammatory mediators in peripheral blood.